PMID: 16628280Apr 22, 2006Paper

Managing thyroid cancer without thyroxine withdrawal

Arquivos brasileiros de endocrinologia e metabologia
Pedro Weslley RosarioSaulo Purisch

Abstract

Thyroxine (T4) withdrawal or recombinant TSH is used for the stimulation of thyroglobulin (Tg), whole-body scanning (WBS) and iodine-131 treatment in patients with thyroid carcinoma. This study evaluated the T4 dose reduction protocol as an alternative for patients' preparation. Fifty-one patients were submitted to total T4 withdrawal for WBS and Tg measurement. T4 treatment was then resumed and maintained until TSH reached levels < 0.3 mIU/l. The T4 dose was then decreased to 0.8 microg/kg/day and TSH was measured weekly. Tg was assayed when TSH was > 30 mIU/l. Patients diagnosed with the disease upon initial evaluation were treated. We also evaluated the clinical and laboratory changes observed for both preparations. Using the reduced dose protocol, TSH levels > 30 mIU/l were reached within 6 and 8 weeks in 84.6 and 100% of the patients, respectively. T4 withdrawal was associated with more common symptoms of hypothyroidism and elevation of creatine kinase (CK) and LDL cholesterol. The T4 dose reduction protocol proved to be useful for Tg stimulation and ablative therapy, without the complication of severe hypothyroidism or the cost of recombinant TSH.

References

Aug 1, 1990·The Journal of Clinical Endocrinology and Metabolism·L J DeGrootF H Straus
May 1, 1984·Digestive Diseases and Sciences·A Dubois, J M Goldman
Apr 1, 1980·The Journal of Clinical Endocrinology and Metabolism·J M GoldmanJ Robbins
Nov 1, 1994·The American Journal of Medicine·E L Mazzaferri, S M Jhiang
Apr 1, 1996·Thyroid : Official Journal of the American Thyroid Association·V Guimaraes, L J DeGroot
Oct 1, 1996·Thyroid : Official Journal of the American Thyroid Association·F S Greenspan
Jan 29, 1998·The New England Journal of Medicine·M J Schlumberger
Apr 16, 1998·European Journal of Endocrinology·M Schlumberger, E Baudin
Nov 24, 1999·The Journal of Clinical Endocrinology and Metabolism·B R HaugenE C Ridgway
Jul 14, 2000·Nuclear Medicine Communications·J M DurskiI R McDougall
Jul 11, 2002·The Journal of Clinical Endocrinology and Metabolism·Richard J RobbinsR Michael Tuttle
Apr 8, 2003·The Journal of Clinical Endocrinology and Metabolism·E L MazzaferriA Pinchera

❮ Previous
Next ❯

Citations

Jul 6, 2013·Arquivos brasileiros de endocrinologia e metabologia·Pedro Weslley RosárioUNKNOWN Sociedade Brasileira de Endocrinologia e Metabologia
Sep 25, 2007·Arquivos brasileiros de endocrinologia e metabologia·Ana Luiza MaiaMario Vaisman

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.